Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Progenics Pharmaceut (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 464,154
  • Shares Outstanding, K 70,220
  • Annual Sales, $ 69,430 K
  • Annual Income, $ 10,810 K
  • 36-Month Beta 3.36
  • Price/Sales 6.65
  • Price/Cash Flow 35.74
  • Price/Book 5.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.48 +0.54%
on 07/27/17
7.02 -7.19%
on 07/12/17
-0.39 (-5.58%)
since 06/27/17
3-Month
6.10 +6.80%
on 05/31/17
8.30 -21.51%
on 05/02/17
-1.20 (-15.61%)
since 04/27/17
52-Week
4.84 +34.61%
on 11/01/16
11.72 -44.41%
on 03/15/17
+0.45 (+7.51%)
since 07/27/16

Most Recent Stories

More News
Shares of PGNX Down 30.4% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ:PGNX) on March 30th, 2017 at $9.67. In approximately 2 months, Progenics Pharmaceuticals has returned 30.42% as of today's recent...

PGNX : 6.53 (-1.21%)
Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today the presentation of two...

PGNX : 6.53 (-1.21%)
Progenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive...

PGNX : 6.53 (-1.21%)
Downtrend Call Working As Progenics Pharmaceuticals Stock Falls 33.5% (PGNX)

SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ:PGNX) on March 30th, 2017 at $9.67. In approximately 2 months, Progenics Pharmaceuticals has returned 33.47% as of today's recent...

PGNX : 6.53 (-1.21%)
Progenics Pharmaceuticals Has Returned 28.1% Since SmarTrend Recommendation (PGNX)

SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ:PGNX) on March 30th, 2017 at $9.67. In approximately 2 months, Progenics Pharmaceuticals has returned 28.09% as of today's recent...

PGNX : 6.53 (-1.21%)
Progenics Pharmaceuticals Shares Down 25.5% Since SmarTrend's Sell Call (PGNX)

SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ:PGNX) on March 30th, 2017 at $9.67. In approximately 2 months, Progenics Pharmaceuticals has returned 25.50% as of today's recent...

PGNX : 6.53 (-1.21%)
Biotech Stocks on Investors' Radar -- Progenics Pharma, Dynavax Technologies, Intrexon, and Heat Biologics

Stock-Callers.com is currently reviewing the most recent performances of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Dynavax Technologies Corp. (NASDAQ: DVAX), Intrexon Corp. (NYSE: XON), and Heat Biologics...

HTBX : 0.51 (-1.92%)
PGNX : 6.53 (-1.21%)
XON : 23.58 (+1.99%)
DVAX : 9.60 (-7.69%)
PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

PETS : 50.02 (-1.03%)
HOLX : 44.96 (-0.40%)
PGNX : 6.53 (-1.21%)
BAX : 60.83 (-0.64%)
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

HOLX : 44.96 (-0.40%)
PGNX : 6.53 (-1.21%)
HSIC : 183.01 (-0.94%)
BAX : 60.83 (-0.64%)
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

HOLX : 44.96 (-0.40%)
PGNX : 6.53 (-1.21%)
BAX : 60.83 (-0.64%)
HAE : 39.57 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Support & Resistance

2nd Resistance Point 6.72
1st Resistance Point 6.66
Last Price 6.53
1st Support Level 6.56
2nd Support Level 6.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.